Mumbai, July 23 -- Nepexto will be promoted by Generic Health, BBL's local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in Australia.

Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.

Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe.

Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is working towards expanding Nepexto into new marke...